Seasonal weak start masks execution risk amid capex fatigue

Delivered revenue ₹315.8 Cr, YoY +3.2% — management's 4.1% overstates by 90 bps

Delivered PAT ₹4.6 Cr; 436.9% YoY growth misleading — Q1 FY26 was loss of ₹1.4 Cr, not comparable base

OPM 7%, NPM 1.4% suggest operating margin well below 9%; 300 bps recovery in 3 quarters difficult given weak Q1

Q1 garment revenue was ₹69 Cr; ₹100 Cr/quarter implies 45% sequential jump with ongoing West Asia logistics risk

Delivered revenue supported; but sequential decline -13.7% QoQ and capacity utilization only 80% suggest demand not as robust

Management signaled shift to 20–25% capacity expansion in fabric & garment for FY27–28, Surat modernization; but decade-long capex history (₹500 Cr, ~1% CAGR) raises credibility risk.

Originally expected earlier; delays in GIDC approvals (now resolved) and customs no-due-certificate pending. Main upside benefit pushed to FY28.

FTA tailwind real but pipeline unproven. EU business (₹100 Cr from Mango + Celio + C&A trials) also emerging. Depends on execution and demand hold.

Implies ₹1,135–1,184 Cr in 9 months (avg ₹126–131 Cr/month vs ₹105 Cr Q1 run rate). Order book booked through Nov but Dec onward uncertain; no capex expansion guide pulled.

Yes, ₹140 Cr planned FY27 for fabric & garment; 20–25% expansion target FY27–28. Already sanctioned & underway.

Garment: 70% of West Asia shipments deferred to Q2; autumn/winter season weak for export. Domestic festive pickup starts July. Expect ₹100 Cr/quarter Q2–Q4 from here.

Q1 always seasonally soft; labor shortages easing; garment order book full through Dec, fabric through Nov; expected recovery Q2–Q3; Q4 historically strongest.

JV with French company dissolved ~decade ago; we lost those sales, had to rebuild without partners. Now have better product mix, FTA tailwinds, market matured (Chinese import displacement). Scenario completely different.

Fabric 12–14%, Garment 8–10%, Yarn 8–10%, consolidated 12%. Q1 achieved 9% but expect full-year average 12%.

GIDC approvals received; pending customs no-due-certificate (3 months), debonding (3–5 months). Target DTA ready by Nov–Dec '26, operational Apr '27. ₹50 Cr fresh investment for modern plant; ₹200 Cr capacity potential.

Fabric ₹70–80 Cr annually to UK; garment ₹20–25 Cr currently, expect ₹50 Cr next year (double). FTA benefits start Q2+.

Surat shutdown was strategic (SEZ → DTA shift for flexibility & better earnings); once reopens Apr '27, new capex pathway opens. Daman facility optimized this year. We are on journey but took longer.

Q1 achieved ₹315.8 Cr; remaining 9 months need ₹1,135–1,184 Cr (~₹126–131 Cr/month avg). Order books booked through Nov-Dec; Dec-Mar (Q4) execution critical.

Q1 delivered 9% EBITDA, 300 bps short. Fabric on track; Yarn/Garment well below guide. Recovery depends on leverage from higher volume (Q2+) and easing cost headwinds (labor, logistics). No contingency disclosed.

Funds already committed. Surat DTA approval on track for Nov–Dec, Apr '27 operations. Indicates management committed but Surat timeline already slipped once.

West Asia crisis caused ~₹15–20 Cr garment shipment deferment in Q1. If crisis escalates or prolongs, further disruptions likely; buyer reluctance to commit.

₹500 Cr invested over 5 yrs delivered <1% revenue CAGR. Surat facility restart (₹50 Cr) delays already (DTA approval pushed to Dec '26, operations Apr '27). If execution slips further, capex burden + weak organic growth will pressure debt/cash.

Garment order book fully booked through Nov/Dec; fabric through Nov. Beyond Dec, no quantified pipeline disclosed. If seasonal Q4 (typically strongest) underperforms or FTA benefits don't materialize as hoped, revenue target at risk.

Q1 EBITDA 9% vs 12% guide (300 bps miss). Yarn at 70% utilization, Garment impacted by logistics costs. Recovery to 12% requires volume leverage + cost normalization; if either slips, full-year margin at risk.

Garment exports only ₹20–25 Cr currently (40% of segment); targeting ₹50 Cr (double) by next year depends on UK FTA tailwind + new customer ramp (C&A trials, NEXT, Haggar). If demand doesn't materialize or competitors capture share, target will miss.